Biocon Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a total annual income of Rs 17,270 crore, representing a 14% growth. Despite a complex geopolitical environment, the company successfully integrated its biosimilars and generics businesses, delivering significant margin expansion and positioning itself for long-term sustainable growth through a consolidated biopharmaceutical strategy.
Financial Performance Overview
Biocon concluded FY26 with robust growth across its core operations. Total annual income stood at Rs 17,270 crore, while EBITDA reached Rs 3,798 crore, reflecting a 25% increase (on a like-to-like basis). The company reported a net profit (before exceptional items) of Rs 436 crore, marking a substantial 323% growth. For the fourth quarter (Q4FY26), total income was Rs 4,569 crore with an EBITDA of Rs 1,073 crore and net profit (before exceptional items) of Rs 179 crore.
Strategic Integration and Segment Highlights
The company successfully executed a pivotal integration of its biosimilars and generics units during the year. The Biosimilars segment emerged as the primary growth driver, contributing 60% to the segmental revenue with annual revenue of Rs 10,431 crore, up 16% YoY. The Generics business recorded revenues of Rs 3,168 crore, an increase of 17% YoY (on a like-to-like basis), supported by strong performance in advanced markets and the launch of new products.
Operations and Future Outlook
Syngene, the research services arm, reported annual revenue of Rs 3,739 crore, maintaining an EBITDA margin of 25%. Across the consolidated entity, Biocon invested Rs 982 crore in R&D, representing 8% of its revenue. With the integration phase successfully completed, the company is shifting its strategic focus from “Preserve” to “Consolidate” for fiscal year 2027. The Board of Directors has recommended a final dividend of Re. 0.50 per share for the fiscal year ended March 31, 2026.
Leadership Updates
Following the successful leadership transition, Shreehas Tambe has assumed the role of CEO & Managing Director effective April 1, 2026, supported by Kedar Upadhye as the new Chief Financial Officer. The company also announced a strengthened Board of Directors, bringing in several experienced industry professionals to guide the next phase of global expansion.
Source: BSE
